Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]
News [7752]
Articles [63]
Editorials [9]
Conferences [207]
elearning [49]
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib...
Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma ( Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia )
29 Sep 2012
Phase I and II trials focus on drug combination slowing development of...
Prof Yossef Yarden - Weizmann Institute of Science, Israel.
Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF ( Prof Yossef Yarden - Weizmann Institute of Science, Israel. )
29 Sep 2012
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy
Prof David Ferry - New Cross Hospital, Wolverhampton, UK
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy ( Prof David Ferry - New Cross Hospital, Wolverhampton, UK )
29 Sep 2012
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib
Dr Tony Mok - Chinese University of Hong Kong
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib ( Dr Tony Mok - Chinese University of Hong Kong )
29 Sep 2012
Sorafenib does not extend overall survival as third or fourth line therapy in...
Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial ( Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain )
29 Sep 2012
iwNHL 10: Advances in the treatment of lymphoma
Dr Wyndham Wilson - National Cancer Institute, Bethesda, MD, USA; Dr Myron...
iwNHL 10: Advances in the treatment of lymphoma ( Dr Wyndham Wilson - National Cancer Institute, Bethesda, MD, USA; Dr Myron Czuczman - Roswell Park Cancer Institute, Buffalo, NY, USA; Professor Michael Pfreundschuh - University of Saarland, Homburg-Saar, Germany; Prof John Gribben - Bart’s and Royal )
26 Sep 2012
Cost effective care and the state of oncology in India
Dr Rajendra Badwe – Tata Memorial Hospital, Mumbai, India
Cost effective care and the state of oncology in India ( Dr Rajendra Badwe – Tata Memorial Hospital, Mumbai, India )
23 Jul 2012
International Network of bio-banks and expert centres
Prof Kurt Zatloukal – Institute of Pathology, Medical University of Graz...
International Network of bio-banks and expert centres ( Prof Kurt Zatloukal – Institute of Pathology, Medical University of Graz, Austria )
23 Jul 2012
Patient's perspective and regulation of treatments
Jean Mossman – Cancer Charity Consultant
Patient's perspective and regulation of treatments ( Jean Mossman – Cancer Charity Consultant )
20 Jul 2012
The ceRNA Hypothesis and the non-coding revolution in cancer research and...
Prof Pier Paolo Pandolfi - Harvard Medical School, Boston, USA
The ceRNA Hypothesis and the non-coding revolution in cancer research and therapy ( Prof Pier Paolo Pandolfi - Harvard Medical School, Boston, USA )
19 Jul 2012
Underlying metabolic pathways in cancer
Dr Arkaitz Carracedo – Ikerbasque, Bilbao, Spain
Underlying metabolic pathways in cancer ( Dr Arkaitz Carracedo – Ikerbasque, Bilbao, Spain )
18 Jul 2012
Potential for micro-RNA based cancer treatments
Prof Carlo Croce – Ohio State University, Columbus, USA
Potential for micro-RNA based cancer treatments ( Prof Carlo Croce – Ohio State University, Columbus, USA )
18 Jul 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation